Vanguard Group Inc ownership in VERA / Vera Therapeutics, Inc.

維拉治療公司

US ˙ NasdaqGM ˙ US92337R1014

Security	VERA / Vera Therapeutics, Inc.
Institution	Vanguard Group Inc
Latest Disclosed Ownership	0 shares
Ownership	0.00%

2026-03-27 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Vera Therapeutics, Inc. (US:VERA). This represents 0.0 percent ownership of the company. In their previous filing dated 2026-01-30 , Vanguard Group Inc had reported owning 3,570,401 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-03-27	2026-03-27	13G/A	3,570,401	0	-100.00	0.00	-100.00
2026-01-30	2026-01-30	13G		3,570,401		5.03

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	VERA THERAPEUTICS	CL A	92337R101	3,570,401	379,748	11.90	180,805	95.00	0.0026
2025-11-07	2025-09-30	13F	VERA THERAPEUTICS	CL A	92337R101	3,190,653	189,545	6.32	92,720	31.13	0.0014
2025-08-11	2025-06-30	13F	VERA THERAPEUTICS	CL A	92337R101	3,001,108	82,685	2.83	70,706	0.86	0.0011
2025-05-09	2025-03-31	13F	VERA THERAPEUTICS	CL A	92337R101	2,918,423	-31,141	-1.06	70,101	-43.80	0.0013
2025-02-11	2024-12-31	13F	VERA THERAPEUTICS	CL A	92337R101	2,949,564	369,387	14.32	124,737	9.38	0.0022
2024-11-13	2024-09-30	13F	VERA THERAPEUTICS	CL A	92337R101	2,580,177	56,001	2.22	114,044	24.88	0.0020
2024-08-13	2024-06-30	13F	VERA THERAPEUTICS	CL A	92337R101	2,524,176	375,462	17.47	91,325	-1.43	0.0018
2024-05-10	2024-03-31	13F	VERA THERAPEUTICS	CL A	92337R101	2,148,714	515,106	31.53	92,653	268.78	0.0018
2024-03-11	2023-12-31	13F/A-1	VERA THERAPEUTICS	CL A	92337R101	1,633,608	59,218	3.76	25,125	16.40	0.0005
2024-02-14	2023-12-31	13F	VERA THERAPEUTICS	CL A	92337R101	1,633,608	59,218		25,125		0.0005
2023-12-18	2023-09-30	13F/A-1	VERA THERAPEUTICS	CL A	92337R101	1,574,390	134,125	9.31	21,585	-6.63	0.0005
2023-11-14	2023-09-30	13F	VERA THERAPEUTICS	CL A	92337R101	1,574,390	134,125		21,585		0.0001
2023-08-14	2023-06-30	13F	VERA THERAPEUTICS	CL A	92337R101	1,440,265	45,414	3.26	23,116	113.56	0.0005
2023-07-14	2023-03-31	13F/A-1	VERA THERAPEUTICS	CL A	92337R101	1,394,851	627,318	81.73	10,824	-27.12	0.0003
2023-05-15	2023-03-31	13F	VERA THERAPEUTICS	CL A	92337R101	1,394,851	627,318		10,824		0.0001
2023-02-10	2022-12-31	13F	VERA THERAPEUTICS	CL A	92337R101	767,533	8,701	1.15	14,852	-8.16	0.0004
2022-11-14	2022-09-30	13F	VERA THERAPEUTICS	CL A	92337R101	758,832	81,895	12.10	16,171	75.50	0.0005
2022-08-12	2022-06-30	13F	VERA THERAPEUTICS	CL A	92337R101	676,937	58,934	9.54	9,214	-36.53	0.0003
2022-05-13	2022-03-31	13F	VERA THERAPEUTICS	CL A	92337R101	618,003	229,025	58.88	14,517	39.67	0.0003
2022-02-14	2021-12-31	13F	VERA THERAPEUTICS	CL A	92337R101	388,978	143,143	58.23	10,394	143.70	0.0002
2021-11-12	2021-09-30	13F	VERA THERAPEUTICS	CL A	92337R101	245,835	193,567	370.34	4,265	515.44	0.0001
2021-08-13	2021-06-30	13F	VERA THERAPEUTICS	CL A	92337R101	52,268	52,268		693		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.